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Abstract
Background: Severe early-onset fetal growth restriction occurs in 0.4 % of all pregnancies, and the prognoses
of these patients are dismal. Severely growth-restricted fetuses (far below 500 g) are thought to be nonviable.
Since there have not been effective treatments for such fetal patients, obstetricians have simply tried to identify the
optimal timing for their delivery. There are a few reports suggesting that the phosphodiesterase type 5 inhibitor
sildenafil has some limited beneficial effects on fetal growth, but there are no such reports on tadalafil, another
derivative phosphodiesterase type 5 inhibitor which has a much longer half-life than sildenafil. Here we present
a case in which the administration of tadalafil to the mother revived the arrested growth and severe
oligohydramnios of the very prematurely growth-restricted fetus.
Case presentation: We describe a case of early-onset fetal growth restriction with oligohydramnios in a 41-year-old
primigravida Japanese woman who was treated with tadalafil (20-mg tablet daily) from 22 weeks’ gestational
age. Ten days after the initiation of the tadalafil therapy, the amniotic fluid level rose and the weight of the
fetus began to increase. A 1024-g baby boy was delivered by cesarean at 32 weeks’ gestation. The z-score for
fetal head circumference had increased from −2.2 to −1.2, whereas the z-score of the femur legth was
decreased to −4.3, indicating that tadalafil preferentially increased the blood flow to important organs.
Conclusions: We achieved two positive results by administering tadalafil to the mother carrying a severely
growth-restricted fetus with oligohydramnios. First, the z-scores of head circumference and abdominal circumference
had at first declined but started to rise after the tadalafil administration. Second, the amniotic fluid, which
was emptied before the tadalafil treatment, recovered to normal range with this treatment. Tadalafil
administration to mothers could be a promising therapy to reverse severe fetal growth restriction and
oligohydramnios.
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Background
The management of fetal growth restriction is based
on the prolongation of gestation long enough for fetal
organs to mature while simultaneously preventing
irreversible deterioration of the fetus’ well-being. This
policy is used because there has been no treatment to
reverse fetal growth in utero until now. The administra-
tion of aspirin or oxygen to the mother and in-patient
bed rest for the mother were all found to have no
beneficial effects on fetal growth in randomized control
studies [1–3]. Several promising therapies are currently
under development to reverse fetal growth restriction [4].
One of these therapies is sildenafil, a phosphodiesterase
(PDE) 5 inhibitor that is used to treat both pulmonary
hypertension and erectile dysfunction. In an open-label
pilot study, treatment with the PDE5 inhibitor sildenafil
seemed to be effective in increasing fetal abdominal
circumference (AC) of patients with early-onset fetal
growth restriction [5].
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The PDE5 inhibitor tadalafil was developed as a medi-
cation that was longer acting than sildenafil (the biological
half-life of tadalafil is 14 to 15 hours versus sildenafil’s
3 hours) for the treatment of pulmonary hypertension,
erectile dysfunction, and prostatic hypertrophy. We
used tadalafil successfully in the following single case
of early-onset severe fetal growth restriction.
Case presentation
At a 19-weeks gestational checkup of a post-in vitro
fertilization pre-embryo transfer (IVF-ET) pregnancy of
a 41-year-old primigravida Japanese woman, the result
of a fetal chromosomal test was normal, and normal
amniotic fluid was observed. At 22 weeks and 4 days,
severe oligohydramnios was observed (the amniotic
fluid index decreased to nearly 0) with the fetal bladder
emptied. The estimated fetal weight was 309 g: −2.6 stan-
dard deviation (SD). As judged by the biparietal diameter
(BPD), the growth of the fetus had been arrested by
nearly 4 weeks.
Our patient started to take a 20-mg tablet of tadalafil
per day after getting permission from our hospital’s
Institutional Review Board (Mie University Hospital
approval #135-392), and informed consent for this
treatment was obtained from our patient and her
husband. Four days after the start of the daily tadalafil
therapy, the fetal bladder started to dilate, and at 10 days
of treatment the amniotic fluid level was increased (Fig. 1).
The weight of the fetus started to rise, and the increase
in the well-being of the fetus was confirmed by the
biophysical score. The mother reported no side effects,
including hypotension and headache. She did not develop
pregnancy-induced hypertension at any time during
the pregnancy.
The weight of the fetus increased by approximately
50 to 100 g per week. The amniotic fluid maximum
vertical distance increased from 0.9 cm to 4.4 cm at
27 weeks’ gestational age, then decreased to <2 cm at
32 week’s gestation. At this time, fetal heart rate monito-
ring showed many variable decelerations, and the fetus
was in the breech position. We informed our patient
about this situation, and after careful consideration she
and her husband chose to continue to the delivery. At
32 weeks 2 days, we performed a cesarean because the
weight of the fetus had reached >1000 g, which is gene-
rally thought to guarantee intact survival [6]. At the
moment of the cesarean delivery, the umbilical artery
pulsatility index (PI) was 0.97, the middle cerebral artery
PI was 1.48, and the ductus venosus wave was negative.
A 1024-g baby boy was delivered without acidemia,
with Apgar scores of 5 and 7 at 1 minute and 5 minutes
after birth. The baby boy is now on an uneventful course
at 3-months old.
Figure 2 shows the changes in z-scores of the size
parameters of the fetus estimated by ultrasonography.
Before the start of tadalafil therapy, the z-scores of
Fig. 1 The estimated weight of the fetus increased, the fetal bladder dilated, and the amniotic fluid level increased after tadalafil therapy.
EFW estimated fetal weight, MVP mean vertical pocket of amniotic fluid, W week
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head circumference (HC), AC, and femur length (FL)
decreased to −2.5. After the completion of the 10-
week tadalafil therapy, the HC z-score increased signi-
ficantly to over −1.5 after 30 weeks’ gestation. The AC
z-score kept up with the standard curve, remaining
between −1.8 and −2.5. On the other hand, the FL z-score
decreased consistently down to −4.3 at 31 gestational
weeks.
Figure 3 shows the changes in the Doppler parameters
of the fetal arteries and veins. The umbilical artery PI
decreased after the tadalafil treatment (from 1.11 to
0.69), although it was within the normal range through-
out our patient’s pregnancy. The PI of the middle cere-
bral artery showed a spearing effect at first (1.15) and
decreased temporarily (1.05) for 1 week after the initi-
ation of the tadalafil treatment, then gradually increased
to 1.5 at 32 weeks’ gestation. Fluctuations of the PI of
the umbilical vein were observed before the tadalafil
therapy, but were not seen 7 days after the completion
of the therapy. The reverse flow of the ductus venosus
seen before the therapy disappeared temporarily, but it
appeared intermittently during the treatment course. As
for the uterine artery velocimetry, the PI value was not
significantly different before or after tadalafil treatment
(0.79 and 0.62 respectively), and notching was not
observed at any time.
A pathological examination of the placenta revealed
excessive torsion of the cord, chorangiosis, and infarc-
tion, which suggested that placental hypoperfusion
may have contributed to the growth of the fetus. There
was no funisitis or chorioamnionitis.
Discussion
This is the first report of tadalafil being used for the
treatment of early-onset fetal growth restriction, to the
best of our knowledge. Twenty mg per day of tadalafil —
which is the same dosage as that used for the treatment
of pulmonary hypertension — not only restarted the
growth of the fetus but also improved the condition of
the fetus, increasing fetal urine and amniotic fluid levels.
Tadalafil was developed in 2009 as a new PDE-5
inhibitor with a longer biological half-life than sildenafil,
and it has recently become more widely used for the
treatment of pulmonary hypertension, erectile dysfunc-
tion, and prostate hypertrophy. Tadalafil has an advan-
tage in that it can be taken even on a full stomach,
unlike sildenafil. To-date, case reports [7, 8] and a small
pilot trial study [5] demonstrated that sildenafil had a
beneficial effect on early-onset fetal growth restriction.
von Dadelszen et al. [5] reported that their group (n = 10)
of cases of fetal growth restriction treated with sildenafil
showed significantly increased ACs compared with a
Fig. 2 Change in the z-scores in head circumference, abdominal circumference, and femur length from before to after tadalafil therapy.
AC abdominal circumference, FL femur length, HC head circumference, SD standard deviation, W week
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group of retrospectively gathered cases of fetal growth
restriction (n = 17). Theoretically, tadalafil seems to be
a better choice than sildenafil because it can achieve
a steadier blood concentration and effects.
The rationale for the use of tadalafil therapy in the
present case – the reason why the fetus would have died
without life-saving intervention – is twofold. First, early-
onset fetal growth restriction that shows umbilical
venous fluctuation and reverse ductus venosus flow,
which were observed in this case, is the strongest predic-
tive factor for intrauterine fetal death [9]. Second, almost
one-half of the reported cases of early-onset fetal growth
restriction were complicated with severe oligohydramnios
and destined to die [10]. We believe that in the present
case the tadalafil therapy contributed to the improved
intrauterine environment and to the extension of the
pregnancy to 32 week’s gestation, and finally to the
uncomplicated post-delivery course.
It is interesting to note the different rates of the
growth curves of the HC, AC, and FL z-scores in our
patient (Fig. 2). The HC z-score increased significantly
after the initiation of tadalafil therapy and finally became
within normal range, whereas the FL z-score progressively
worsened to −4.3. The AC z-score remained between
−1.8 and −2.5. These findings indicate that tadalafil
preferentially dilates the fetal arteries and distributes
blood flow to more important organs such as the
brain. In contrast, tadalafil might have increased the
placental circulation through the internal iliac arteries
at the expense of the blood flow of the external iliac
arteries to inferior extremities.
The umbilical artery PI decreased after the initiation
of tadalafil treatment in the present case, as Dastjerdi
et al. reported for sildenafil [11], whereas the middle
cerebral artery PI temporarily decreased for 1 week after
the initiation of tadalafil treatment in our patient, unlike
the Dastjerdi report. This result indicates that tadalafil
was transferred through the placenta and dilated the
cerebral arteries as well as placental arteries, even as
its brain-sparing effect had already been exerted.
Another interesting finding in the present case was
that the reverse flow of the ductus venosus appeared
intermittently after the normalization that was induced
by tadalafil therapy. This indicates that tadalafil dilated
not only arteries but also veins of the placenta, which
led to an increase in the venous flow to the heart, mani-
fested as a reverse return of the ductus venosus.
A limitation of this case report is that it involves only
one case, and thus no conclusions can be made regard-
ing the best timing for tadalafil treatment or its potential
maternal and fetal adverse effects (including long-term
effects), or the evolution of Doppler parameters.
Fig. 3 The parameters of the Doppler examination for fetal arteries and veins. DV-a (rev) reverse flow of ductus venosus a-wave, MCA-PI middle
cerebral artery pulsatility index, PI pulsatility index, UA-PI umbilical artery pulsatility index, UV umbilical vein, W week
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Conclusions
Tadalafil administration to mothers could be a promising
therapy to reverse severe fetal growth restriction and
oligohydramnios. However, the present case highlights
the need for further research about this use of tadalafil,
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